中药注射液治疗放射性肺炎的系统评价和 Meta 分析方案。
Chinese herbal injections for radiation pneumonitis: A protocol for systematic review and meta-analysis.
机构信息
Guang'an men Hospital, China Academy of Chinese Medical Sciences, China.
Beijing University of Chinese Medicine, China.
出版信息
Medicine (Baltimore). 2022 Feb 25;101(8):e28929. doi: 10.1097/MD.0000000000028929.
BACKGROUND
Radiation pneumonitis is a common dose-limiting factor in radiotherapy for thoracic malignancies, and its treatment encounters a bottleneck. As an essential adjuvant treatment method, Chinese herbal injections (CHIs) have been used to treat radiation pneumonitis (RP), and clinical studies have appeared potentially beneficial and nontoxic. However, the efficacy and safety of CHIs for RP have not been evaluated comprehensively.
METHODS
The systematic review and meta-analysis will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) statement guidelines. The Cochrane Library, PubMed, EMBASE, SinoMed, CNKI, VIP, and Wan Fang Databases were systematically searched from inception until January 20, 2022. The selection of studies, data extraction, and assessment of the risk of bias will be performed by 2 reviewers independently. The total effective rate was used as a primary outcome measure; the secondary outcomes are quality of life, clinical symptoms and signs, inflammatory cytokines, and adverse effects. Cochrane Review Manager (RevMan5.3) software will be used for data synthesis and analysis.
RESULTS AND CONCLUSION
This systematic review will evaluate the efficacy and safety of CHIs in treating radiation pneumonitis to provide more comprehensive evidence for the treatment of clinical RP.
INPLASY REGISTRATION NUMBER
INPLASY202210106.
背景
放射性肺炎是胸部恶性肿瘤放射治疗的常见剂量限制因素，其治疗存在瓶颈。中药注射剂（CHIs）作为一种重要的辅助治疗方法，已被用于治疗放射性肺炎（RP），且临床研究显示其具有潜在的益处且无毒。然而，CHIs 治疗 RP 的疗效和安全性尚未得到全面评估。
方法
该系统评价和荟萃分析将根据系统评价和荟萃分析报告的首选报告项目（PRISMA-P）声明指南进行。从创建到 2022 年 1 月 20 日，系统地检索了 Cochrane 图书馆、PubMed、EMBASE、SinoMed、CNKI、VIP 和万方数据库。由 2 名评审员独立进行研究选择、数据提取和偏倚风险评估。总有效率作为主要结局指标；次要结局指标是生活质量、临床症状和体征、炎症细胞因子和不良反应。Cochrane 评论管理软件（RevMan5.3）将用于数据综合和分析。
结果和结论
本系统评价将评估 CHIs 治疗放射性肺炎的疗效和安全性，为临床 RP 的治疗提供更全面的证据。
国际前瞻性注册号
INPLASY202210106。
Zotero 插件